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Research Round Up- Prescribing in End of Life Care 
Introduction 
The last research round up provided an overview of recent research around prescribing opioid 
medications. In this month’s review of recent publications we will build upon the theme of opioids 
by looking at prescribing medication and symptom management in end of life care. Many of you will 
have experience of caring for people at the end of their life whether that be in their home setting, 
hospice setting or in hospital.  
Anticipatory prescribing in end of life care 
Two publications reviewed look at the prescribing of anticipatory medications at the end of life. 
In this learning article recently reproduced in the palliative care section of the Pharmaceutical 
Journal. Linda Johnstone discusses the role of pharmacists in providing practical support and advice 
to other healthcare professionals on the prescribing and administration of anticipatory medicines 
and to facilitate timely supply in a community setting. She defines anticipatory prescribing as ‘the 
proactive prescribing of medicines that are commonly required to control symptoms in the last days 
of life’. There is the suggestion that the community pharmacist could advise and support in the 4 key 
areas of anticipatory prescribing,  
• Initiating the conversation with the patient and their family 
• Writing the prescription 
• Dispensing the medicines 
• Administering the medicines to the patient. 
This advice and support is deemed as important for GPs as it is for independent non-medical 
prescribers as prescribing in anticipation of symptoms is a specialist area. The article outlines the 
symptoms to be expected as patients approach the end of life including pain, nausea and vomiting, 
delirium and agitation, terminal restlessness, and respiratory secretions. It reinforces that 
medication for these symptoms should be prescribed as per local policy, while considering individual 
patient need. It suggests that people with non-malignant terminal disease may pose different and 
complex challenges to prescribers and the support from the pharmacist centres around additional 
medications or modification of standard guidelines. 
The article also recommends familiarity with guidance from the British Medical Association around 
accepting responsibility for anticipatory prescribing while being mindful of the need for monitoring 
and review so that clinical assessment can take place when the patient’s condition alters. The article 
has some useful practical tips for pharmacists and prescribers working in this area. 
Johnstone, L. (2017) Facilitating Anticipatory Prescribing in End-of-Life-Care The Pharmaceutical 
journal.  Retrieved from https://www.pharmaceutical-journal.com/cpd-and-learning/learning-
article/facilitating-anticipatory-prescribing-in-end-of-life-care/20202703.article 
 
This second, open access article looks at the impact of the COVID-19 pandemic on anticipatory 
prescribing for end of life care in the community in the UK and Ireland. Utilising and online survey 
methodology this study aimed to investigate clinician’s experiences of reported changes to 
prescribing guidelines and practice during the COVID-19 pandemic. The population surveyed was 
drawn from participants at previous anticipatory prescribing workshops, members of the Association 
for Palliative Medicine of Great Britain and Ireland and other professional organisations, with 
snowball sampling. The responses were received over a ten-day period in April 2020, with 261 
completed online surveys returned. The responses varied in clinical setting including hospice, 
community settings and hospital sites across the UK and Ireland. Changes to anticipatory prescribing 
practice was reported and the areas of these changes were reported as: route of administration 
(47%), drugs prescribed (38%), total quantities prescribed (35%), doses and ranges (29%). Concerns 
over shortages of nurses and doctors to administer subcutaneous injections led 37% to consider 
drug administration by family or social caregivers, often by buccal, sublingual, and transdermal 
routes. Clinical contact and patient assessment were more often remote via telephone or video 
(63%). Recommendations for regulatory changes to permit drug repurposing and easier community 
access were made. The authors conclude that the challenges presented by the COVID-19 pandemic 
for UK community palliative care has stimulated rapid innovation in anticipatory prescribing. They 
also suggest that the extent to which these are implemented, and their clinical efficacy need further 
examination. 
Antunes B, et al. (2020) Anticipatory Prescribing in community end of life care in the UK and Ireland 
during the COVID-19 pandemic: online survey   BMJ Supportive & Palliative Care;0:1–7. 
doi:10.1136/bmjspcare-2020-002394 retrieved from 
https://spcare.bmj.com/content/bmjspcare/early/2020/06/15/bmjspcare-2020-002394.full.pdf 
 
End of Life Care in COVID-19 
This short report in the journal of Palliative Medicine sought to review whether prescribing for 
symptom control in patients dying with COVID-19 adhered to existing local guidance or whether 
there was deviation which may represent a need for revised guidance or specialist support in 
particular patient groups. The authors reviewed the electronic patient records of inpatients who had 
died over a 4-week period in March/April 2020, who had tested positive for COVID-19 after swab 
testing and had been referred to the inpatient palliative care service. This resulted in the inclusion in 
the study of 61 patient records for retrospective review. The review went on to exclude 13 records 
from the final inclusion for analysis due to; death before review, dying phase not identified and 
those patients receiving invasive ventilation. The results of this final audit showed that 83% (40/48) 
of patients who were prescribed opioids had this done at a starting dose consistent with existing 
local guidelines. In the remaining 17% who were prescribed a higher dose, 7 of the 8 identified had 
this higher dose prescribed on the direct advice of the inpatient palliative care team for clinical 
reasons including not being opioid naive. Other outcomes identified included mean total opioid 
doses, mean total midazolam doses and also doses given in patients receiving non invasive 
ventilation support.  
The authors conclude that despite the COVID-19 pandemic, prescribing of end of life drugs for 
symptom control followed existing guidance. That which fell outwith the normal ranges an initiation 
was done so on an individual patient need basis and was not done as routine but was supported by 
the inpatient palliative care team.  
Jackson, T., Hobson, K., Clare, H., Weegmann, D., Moloughney, C & McManus, S. (2020) End-of-life 
care in COVID-19: An audit of pharmacological management in hospital inpatients. Palliative 
Medicine. Retrieved from https://journals.sagepub.com/doi/pdf/10.1177/0269216320935361 
 
 
Supporting medicines management at home in end of life care 
This open access article describes a study that aimed to explore how healthcare professionals 
describe the support they provide for patients to manage medications at home at end of life. The 
researchers conducted qualitative interviews to elicit themes around the area of study. They 
sampled community healthcare professionals in a purposive and snowball manner. This resulted in 
40 interviews with a diverse population of professionals including GPs, pharmacists, and a range of 
nurses within 2 counties in England. Interviews were conducted between June 2017 and October 
2018 and used a schedule to guide the discussion. The focus was to explore issues for patients and 
carers around managing medications at home at the end of life, and how they supported them in 
managing these issues. A range of support mechanisms were identified to try to ensure patients 
managed their medications appropriately at the end of life so they could be administered as 
prescribed. These included reducing polypharmacy where possible, use of different formulations to 
aid administration, administration aids such as Dosette boxes or blister packs and ensuring 
information and education on the drugs was provided. Other issues around substance misuse and 
diversion were identified and target strategies suggested to manage these situations. They conclude 
that this are requires more detailed investigation and the authors recommend a more proactive 
approach to supporting patients and carers in managing medicines at the end of life. General 
processes should be in place but with the flexibility to tailor support to individual patient needs. 
Wilson, E., Caswell, G., Latif, A., Anderson, C., Faull, C. & Pollock, K. (2020) An exploration of the 
experiences of professionals supporting patients approaching the end of life in medicines 




The area of prescribing in end of life care presents the prescriber with a wide range of challenges, 
especially considering the recent changes seen due to COVID-19. Prescribers need to be aware of 
guidelines supporting prescribing decision making but also the need to tailor the clinical 
interventions to meet patient’s needs. 
 
